Wet Macular Degeneration Market - Forecast(2020 - 2025)

Report Code: HCR 0596 Report Format: PDF + Excel (Delivery in 48 Hrs)
Wet Macular Degeneration Market Overview
Wet Macular Degeneration Market size is forecast to reach $8.71 billion by 2025, growing at a CAGR of 8.11% during the forecast period 2020-2025.Increasing prevalence of eye disorder and increasing geriatric population are the major factors driving the growth of the market. Growing number of drug approvals is set to further enhance the overall market demand wet macular degeneration   during the forecast period 2020-2025. 

Report Coverage
The report: “Wet Macular Degeneration Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Wet Macular Degeneration Market. 

By Drug: Lucentis, Eylea, Avastin and Others
By Route of Administration:  Intravitreal and Intravenous
By End User: Hospitals, Clinics, Research Institutes and Academic Institutes
By Geography: North America, Europe, Asia Pacific and Rest of the World (RoW)

Key Takeaways
  • North America dominated the Wet Macular Degeneration Market in 2019 owing to increasing geriatric population and growing number of drug approvals by the key players present in this region. The Wet Macular Degeneration Market scope for different regions will be provided in the final report.
  • Increasing prevalence of wet macular degeneration and rise in demand for Eylea is likely to aid in the market growth of wet macular degeneration.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Wet Macular Degeneration Market report.
  • High cost of on label drugs and increase in off label drugs is set to create hurdles for the Wet Macular Degeneration Market.

Drug - Segment Analysis
The Eylea segment held the largest share in the Wet Macular Degeneration Market in 2019 and is estimated to grow at a CAGR of 6.39% during the forecast period 2020-2025. This is  owing to the increasing prevalence of wet macular degeneration and rise in demand for Eylea. In people with certain types of eye disorders, new blood vessels grow under the retina where they leak blood and fluid. Lucentis is used to treat the wet form of age-related macular degeneration. Lucentis is also used to treat swelling in the retina caused by diabetes or by a blockage in the blood vessels. Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For wet macular degeneration it is given by injection into the eye and it is estimated that eylea is set to be the fastest growing segment during the forecast period 2020-2025.

Route of Administration - Segment Analysis
Intravitreal segment held the largest share in the Wet Macular Degeneration Market in 2019 owing as it is more effective owing to targeted drug delivery. An intravitreal injection is a shot of medicine into the eye. The inside of the eye is filled with a jelly-like fluid (vitreous). Most anti-VEGF injections are administered using intravitreal or intraocular injections. Intravenous is therapy that delivers fluids directly into a vein. The intravenous route of administration can be used both for injections, using a syringe at higher pressures; as well as for infusions, typically using only the pressure supplied by gravity. Intravenous infusions are commonly referred to as drips. Intravitreal is estimated to be the highest growing segment during the forecast period 2020-2025 boosting the growth of the Wet Macular Degeneration Market.

Geography - Segment Analysis
North America dominated the wet macular degeneration market in 2019 with a share of more than 38.5%, followed by Asia Pacific owing to the increasing prevalence of wet macular degenerative as well as the rising number of drug approvals in the region.
However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the growing geriatric population and prevalence of eye disorder along with the increase in pipeline drugs.

Drivers – Wet Macular Degeneration Market 
  • Increasing prevalence of eye disorder
Increasing prevalence of eye disorder is increasing the wet macular degeneration market. Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It’s generally caused by abnormal blood vessels that leak fluid or blood into the macula. Wet macular degeneration symptoms usually appear suddenly and worsen rapidly. This include-Visual distortions, such as straight lines seeming bent , Reduced central vision in one or both eyes , decreased intensity or brightness of colors , a well-defined blurry spot or blind spot in your field of vision . A general haziness in your overall vision, abrupt onset and rapid worsening of symptoms. No one knows the exact cause of wet macular degeneration, but it develops in people who have had dry macular degeneration. Of all people with age-related macular degeneration, about 10 percent have the wet form. Thus, increasing the growth of the wet macular degeneration market during the forecast period 2020-2025.
  • Increasing prevalence of wet macular degeneration  and rise in demand for Eylea 
Increasing prevalence of wet macular degeneration and rise in demand of eylea is increasing the growth of the wet macular degeneration market. Eylea is a prescription medicine given by injection into the eye. One should not use EYLEA if they have an infection in or around the eye, eye pain or redness or known allergies to any of the ingredients in EYLEA, including aflibercept. EYLEA is an anti-vascular endothelial growth factor (anti-VEGF) treatment that is given by injection into the eye and works by blocking VEGF. EYLEA blocks VEGF by trapping it between its molecular arms. Eylea is used in the treatment of wet macular degeneration. Thus, increasing the demand of wet macular degeneration market.

Challenges – Wet Macular Degeneration Market 
  • High cost of on label  drugs and increase in off label drugs 
Some of the factors which can impede the growth of the wet macular degeneration market are high cost of on label drugs and increase in off label drugs.

Wet Macular Degeneration Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the wet macular degeneration market. In 2019, Wet Macular Degeneration Market share is consolidated by the top ten players present in the market. Wet Macular Degeneration, top 10 companies are Pfizer Inc., F. Hoffmann-La Roche, Regeneron Pharmaceutical, Novartis Ag, Valeant Pharmaceutical International, Inc., Apellis Pharmaceuticals Inc., GlaxoSmithKline plc, Bausch Health Companies Inc., Ophthotech Corporation and Gilead Sciences Inc. among others. 
  
Acquisitions/Product Launches
  • In January 2019, GlaxoSmithKline plc acquired Tesaro.
  • In November 2018, Ophthotech Corporation acquires Versant ventures backed inception 
1. Wet Macular Degeneration Market - Overview
    1.1 Definitions and Scope
2. Wet Macular Degeneration Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Drug 
    2.3 Key trends by Route of Administration
    2.4 Key trends by End User
    2.5 Key trends by Geography
3. Wet Macular Degeneration Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Wet Macular Degeneration Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Wet Macular Degeneration Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Wet Macular Degeneration Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Wet Macular Degeneration Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Wet Macular Degeneration Market – By Drug (Market Size –$Million/$Billion)
    8.1 Lucentis
    8.2 Eylea
    8.3 Avastin
    8.4 Others
9. Wet Macular Degeneration Market  – By Route of administration(Market Size –$Million/$Billion)
    9.1 Intravitreal
    9.2 Intravenous
10. Wet Macular Degeneration Market  – By End User (Market Size –$Million/$Billion)
    10.1 Hospitals
    10.2 Clinics
    10.3 Research Institutes
    10.4 Academic institutes
11. Wet Macular Degeneration Market - By Geography 
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia
        11.3.6 New Zealand
        11.3.7 Rest of APAC
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Wet Macular Degeneration Market - Entropy
13. Wet Macular Degeneration Market – Industry/Segment Competition Landscape   (Premium) 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Wet Macular Degeneration Market – Key Company List by Country Premium (Premium)
15. Wet Macular Degeneration Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.